The role of targeted therapy in ovarian cancer
Abstract Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2011-09, Vol.47, p.S116-S130 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S130 |
|---|---|
| container_issue | |
| container_start_page | S116 |
| container_title | European journal of cancer (1990) |
| container_volume | 47 |
| creator | Banerjee, Susana Kaye, Stan |
| description | Abstract Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic. |
| doi_str_mv | 10.1016/S0959-8049(11)70155-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_898504001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804911701551</els_id><sourcerecordid>898504001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-5b65be87825d9ad935c54e3fde78a910654264050c97ed7c2e9b3f5075d4e07b3</originalsourceid><addsrcrecordid>eNqFkMFO3DAQQC3UqizQT6DKreUQOpN4YvtSVKEClZB6KJwtx54U02yytbNI-_fN7gKHXnqay5s3mifEKcI5Ajaff4IhU2qQ5hPimQIkKvFALFArU4Km6o1YvCKH4ijnRwBQWsI7cVihkbVpaCHO7x64SGPPxdgVk0u_eOJQTA-c3GpTxKEYn1yKbii8GzynE_G2c33m98_zWNxffbu7vClvf1x_v_x6W3qpaSqpbahlrXRFwbhgavIkue4CK-0MQkOyaiQQeKM4KF-xaeuOQFGQDKqtj8XHvXeVxj9rzpNdxuy5793A4zpbbTSBBMCZpD3p05hz4s6uUly6tLEIdlvK7krZbQaLaHel7Hbvw_OFdbvk8Lr1kmYGLvYAz38-RU42-8hzhBAT-8mGMf73xJd_DL6PQ_Su_80bzo_jOg1zRIs2Vxb2kq0DcWfA-i9sOIsm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898504001</pqid></control><display><type>article</type><title>The role of targeted therapy in ovarian cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Banerjee, Susana ; Kaye, Stan</creator><creatorcontrib>Banerjee, Susana ; Kaye, Stan</creatorcontrib><description>Abstract Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(11)70155-1</identifier><identifier>PMID: 21943965</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Carcinoma - blood supply ; Carcinoma - therapy ; Clinical Trials, Phase I as Topic - methods ; Clinical Trials, Phase II as Topic - methods ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Models, Biological ; Molecular Targeted Therapy - methods ; Molecular Targeted Therapy - utilization ; Ovarian Neoplasms - blood supply ; Ovarian Neoplasms - therapy ; Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><ispartof>European journal of cancer (1990), 2011-09, Vol.47, p.S116-S130</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-5b65be87825d9ad935c54e3fde78a910654264050c97ed7c2e9b3f5075d4e07b3</citedby><cites>FETCH-LOGICAL-c485t-5b65be87825d9ad935c54e3fde78a910654264050c97ed7c2e9b3f5075d4e07b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0959-8049(11)70155-1$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21943965$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Banerjee, Susana</creatorcontrib><creatorcontrib>Kaye, Stan</creatorcontrib><title>The role of targeted therapy in ovarian cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Abstract Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma - blood supply</subject><subject>Carcinoma - therapy</subject><subject>Clinical Trials, Phase I as Topic - methods</subject><subject>Clinical Trials, Phase II as Topic - methods</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Models, Biological</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Molecular Targeted Therapy - utilization</subject><subject>Ovarian Neoplasms - blood supply</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFO3DAQQC3UqizQT6DKreUQOpN4YvtSVKEClZB6KJwtx54U02yytbNI-_fN7gKHXnqay5s3mifEKcI5Ajaff4IhU2qQ5hPimQIkKvFALFArU4Km6o1YvCKH4ijnRwBQWsI7cVihkbVpaCHO7x64SGPPxdgVk0u_eOJQTA-c3GpTxKEYn1yKbii8GzynE_G2c33m98_zWNxffbu7vClvf1x_v_x6W3qpaSqpbahlrXRFwbhgavIkue4CK-0MQkOyaiQQeKM4KF-xaeuOQFGQDKqtj8XHvXeVxj9rzpNdxuy5793A4zpbbTSBBMCZpD3p05hz4s6uUly6tLEIdlvK7krZbQaLaHel7Hbvw_OFdbvk8Lr1kmYGLvYAz38-RU42-8hzhBAT-8mGMf73xJd_DL6PQ_Su_80bzo_jOg1zRIs2Vxb2kq0DcWfA-i9sOIsm</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Banerjee, Susana</creator><creator>Kaye, Stan</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>The role of targeted therapy in ovarian cancer</title><author>Banerjee, Susana ; Kaye, Stan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-5b65be87825d9ad935c54e3fde78a910654264050c97ed7c2e9b3f5075d4e07b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma - blood supply</topic><topic>Carcinoma - therapy</topic><topic>Clinical Trials, Phase I as Topic - methods</topic><topic>Clinical Trials, Phase II as Topic - methods</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Models, Biological</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Molecular Targeted Therapy - utilization</topic><topic>Ovarian Neoplasms - blood supply</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banerjee, Susana</creatorcontrib><creatorcontrib>Kaye, Stan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Banerjee, Susana</au><au>Kaye, Stan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of targeted therapy in ovarian cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>47</volume><spage>S116</spage><epage>S130</epage><pages>S116-S130</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Abstract Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21943965</pmid><doi>10.1016/S0959-8049(11)70155-1</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2011-09, Vol.47, p.S116-S130 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_898504001 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Agents - therapeutic use Carcinoma - blood supply Carcinoma - therapy Clinical Trials, Phase I as Topic - methods Clinical Trials, Phase II as Topic - methods Female Hematology, Oncology and Palliative Medicine Humans Models, Biological Molecular Targeted Therapy - methods Molecular Targeted Therapy - utilization Ovarian Neoplasms - blood supply Ovarian Neoplasms - therapy Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| title | The role of targeted therapy in ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A25%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20targeted%20therapy%20in%20ovarian%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Banerjee,%20Susana&rft.date=2011-09-01&rft.volume=47&rft.spage=S116&rft.epage=S130&rft.pages=S116-S130&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(11)70155-1&rft_dat=%3Cproquest_cross%3E898504001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=898504001&rft_id=info:pmid/21943965&rft_els_id=1_s2_0_S0959804911701551&rfr_iscdi=true |